Intrexon Corp (NYSE:XON) has earned an average recommendation of “Hold” from the seven brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $31.67.

XON has been the topic of a number of research analyst reports. Bank of America downgraded shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 price objective on the stock. in a report on Monday, July 16th. Zacks Investment Research downgraded shares of Intrexon from a “buy” rating to a “hold” rating in a report on Monday, July 16th. Stifel Nicolaus initiated coverage on shares of Intrexon in a report on Tuesday, July 17th. They set a “buy” rating and a $72.00 price objective on the stock. Finally, ValuEngine raised shares of Intrexon from a “strong sell” rating to a “sell” rating in a report on Monday, August 20th.

Shares of Intrexon stock traded up $0.31 during trading on Friday, hitting $16.49. 1,251,249 shares of the stock were exchanged, compared to its average volume of 1,583,386. The stock has a market cap of $2.47 billion, a P/E ratio of -17.92 and a beta of 1.09. Intrexon has a 12-month low of $10.26 and a 12-month high of $20.35. The company has a current ratio of 1.78, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01.

Intrexon (NYSE:XON) last released its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.28). The company had revenue of $45.30 million for the quarter, compared to analysts’ expectations of $51.70 million. Intrexon had a negative return on equity of 16.67% and a negative net margin of 82.17%. During the same period in the prior year, the firm posted ($0.16) EPS. As a group, sell-side analysts forecast that Intrexon will post -0.79 earnings per share for the current fiscal year.

In related news, insider Helen Sabzevari sold 8,402 shares of the business’s stock in a transaction dated Wednesday, July 18th. The shares were sold at an average price of $14.54, for a total transaction of $122,165.08. Following the sale, the insider now owns 25,000 shares of the company’s stock, valued at $363,500. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 48.20% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Northern Trust Corp lifted its holdings in shares of Intrexon by 123.1% in the second quarter. Northern Trust Corp now owns 917,510 shares of the biotechnology company’s stock valued at $12,791,000 after purchasing an additional 506,186 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Intrexon by 18.4% in the second quarter. Bank of New York Mellon Corp now owns 278,611 shares of the biotechnology company’s stock valued at $3,884,000 after purchasing an additional 43,310 shares during the period. California Public Employees Retirement System boosted its stake in shares of Intrexon by 96.3% in the second quarter. California Public Employees Retirement System now owns 58,632 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 28,762 shares during the period. Peloton Wealth Strategists boosted its stake in shares of Intrexon by 12.7% in the second quarter. Peloton Wealth Strategists now owns 39,900 shares of the biotechnology company’s stock valued at $556,000 after purchasing an additional 4,500 shares during the period. Finally, MetLife Investment Advisors LLC purchased a new position in shares of Intrexon in the second quarter valued at $457,000. 84.92% of the stock is currently owned by institutional investors.

Intrexon Company Profile

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Featured Story: How to Track your Portfolio in Google Finance

Analyst Recommendations for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.